Login

Forgot your password?
New User?
Remember me
banner banner

You are here:Home » Antibodies » Abs to Cancer Markers » Anti -Prostate Specific Membrane Antigen (PSMA, PSM, Folate Hydrolase, FOLH, FGCP, Glutamate Carboxypeptidase 2, GCP2, Membrane Glutamate Carboxypeptidase, mGCP, N-acetylated alpha-linked Acidic Dipeptidase 1, NAALAD1, NAALADase I, NAALAdase, Pteroylpoly gamma

Anti -Prostate Specific Membrane Antigen (PSMA, PSM, Folate Hydrolase, FOLH, FGCP,
Glutamate Carboxypeptidase 2, GCP2, Membrane Glutamate Carboxypeptidase, mGCP,
N-acetylated alpha-linked Acidic Dipeptidase 1, NAALAD1, NAALADase I, NAALAdase,
Pteroylpoly gamma

Pricing

  For pricing information, USA customers sign in.
  Outside USA? Please contact your distributor for pricing.

Specifications

Clone Host Grade Applications
Monoclonal Mouse Affinity Purified E B IH IF
PSMA (prostate specific membrane antigen) is a type II, integral membrane glycoprotein,1 composed of a 19 amino acid intracellular domain containing the N-terminus, a 24 amino acid transmembrane region, and a 707 amino acid extracellular C-terminal domain. The PSMA gene has been cloned and sequenced, and has been localized to chromosome 11q. PSMA is highly expressed in prostate secretory-acinar epithelium, in some benign extraprostatic epithelial cells from breast, duodenum, and kidney tissues, and in prostate cancer.2 On the basis of its highly prostate-specific nature, PSMA has been used as a prostate cancer marker antigen and diagnostic target for prostate cancer detection. Recently, evidence of limited and specific endothelial PSMA expression has been discovered: the neovasculature of a wide variety of malignant neoplasms (lung, colon, breast, etc.) demonstrates PSMA expression. This finding suggests that PSMA may be an effective target for monoclonal antibody-based anti-neovasculature therapy.2 This may be particularly true for antibodies directed against epitopes within the C-terminal region of PSMA, based on the high degree of accessibility for antibody binding due to the extracellular location of this domain.3 PSMA has also been identified in the human nervous system. Based on activity, immunoreactivity, and mRNA sequence comparison with one form of NAALADase, a neuropeptide that may modulate glutaminergic transmission in the nervous system, PSMA was found to be indistinguishable from NAALADase derived from human cerebellar cell isolates. Therefore, the form of NAALADase also known as PSMA is expressed in brain, where it makes up a significant fraction of brain NAALADase activity
Catalog #P9054-63L
ApplicationsSuitable for use in ELISA, Western Blot, Immunofluorescence and Immunohistochemistry. Other applications not tested.
Recommended DilutionImmunohistochemistry: Formalin-fixed paraffin embedded and frozen tissue sections.
Optimal dilutions to be determined by the researcher.
HybridomaSp2/0-Ag14 myeloma cells with spleen cells from Balb/c mice.
Storage and StabilityMay be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Clone TypeMonoclonal
IsotypeIgG2b,k
Clone No3H266
HostMouse
SourceHuman
Concentration~1mg/ml
FormSupplied as a liquid in PBS, pH 7.0.
PurityPurified by Protein G affinity chromatography.
ImmunogenCrude membrane protein preparation from pooled prostate malignant carcinoma from China.
SpecificityRecognizes human PSMA expressed LNCap cell lines. Little or no crossreactivity to benign prostate hyperplasia (BPH) or to normal prostatic tissue.
Important NoteThis product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.


External Links